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Abstract: Mitochondrial disorders cause energy failure and metabolic derangements. Metabolome
profiling in patients and animal models may identify affected metabolic pathways and reveal new
biomarkers of disease progression. Using liver metabolomics we have shown a starvation-like
condition in a knock-in (Bcs1lc.232A>G) mouse model of GRACILE syndrome, a neonatal lethal
respiratory chain complex III dysfunction with hepatopathy. Here, we hypothesized that a
high-carbohydrate diet (HCD, 60% dextrose) will alleviate the hypoglycemia and promote survival
of the sick mice. However, when fed HCD the homozygotes had shorter survival (mean ± SD,
29 ± 2.5 days, n = 21) than those on standard diet (33 ± 3.8 days, n = 30), and no improvement in
hypoglycemia or liver glycogen depletion. We investigated the plasma metabolome of the HCD-
and control diet-fed mice and found that several amino acids and urea cycle intermediates were
increased, and arginine, carnitines, succinate, and purine catabolites decreased in the homozygotes.
Despite reduced survival the increase in aromatic amino acids, an indicator of liver mitochondrial
dysfunction, was normalized on HCD. Quantitative enrichment analysis revealed that glycine, serine
and threonine metabolism, phenylalanine and tyrosine metabolism, and urea cycle were also partly
normalized on HCD. This dietary intervention revealed an unexpected adverse effect of high-glucose
diet in complex III deficiency, and suggests that plasma metabolomics is a valuable tool in evaluation
of therapies in mitochondrial disorders.
Keywords: mitochondrial disorder; BCS1L; mouse model; metabolite; dextrose diet; nutrition;
GRACILE syndrome
1. Introduction
Mitochondrial disorders are caused by mutations or deletions in mitochondrial (mtDNA) or
nuclear (nDNA) DNA affecting the respiratory chain or other mitochondrial functions. Mitochondrial
dysfunction affects tissues with high energy demand in a highly variable manner at different ages,
but neonates are especially vulnerable to low energy availability. Several neonatal mitochondrial
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disorders present with fetal growth restriction associated with hepatopathy and energy failure, and
recently many causative mutations have been identified in specific genes such as BCS1L, DGUOK,
MPV17, POLG, SCO1, and TFAM [1–3]. BCS1L mutations are the most common cause for CIII
dysfunction [4]. The most severe BCS1L-related disorder is GRACILE syndrome that manifests as fetal
onset growth restriction, aminoaciduria due to proximal tubulopathy, hepatopathy with cholestasis
and iron overload, lactic acidosis, and early death [5–7]. The causative homozygous missense mutation
(c.232A>G) resulting in substitution of serine with glycine (p.S78G) in the protein is almost exclusively
found in individuals with Finnish ancestry. BCS1L is an assembly factor for respiratory chain (RC)
complex III (CIII), needed for the incorporation of the electron-transferring subunit Rieske iron-sulfur
protein (RISP) into the complex.
Mitochondrial disorders still lack efficient treatments, and animal models have proven instrumental
in investigations of possible therapeutic interventions. We have generated a knock-in mouse
model (harboring the Bcs1lc.232A>G mutation) for GRACILE syndrome. The homozygous mutant
mice (Bcs1lG/G) have early liver glycogen depletion, failure to grow, low blood glucose, and rapid
deterioration at about 1 month of age. Liver tissue metabolomics analyses during disease progression
showed an initial decrease in carbohydrate intermediates indicating increased glycolysis (Warburg
effect) to compensate for decreased ATP production [8].
Recent studies have suggested potential beneficial effects of dietary modification in mitochondrial
disorders [9–14]. We hypothesized that the fatigue and acute mortality in Bcs1lG/G mice is related to
hypoglycemia and that by increasing dietary glucose availability their glycemic balance and energy
production through glycolysis would be improved. Therefore, we set out to investigate, whether a
high carbohydrate diet (HCD) containing dextrose would ameliorate disease severity and improve
survival in comparison with normal standard chow diet.
2. Results
2.1. Reduced Survival and No Effect on Blood Glucose or Weight by High Carbohydrate Diet (HCD) Feeding
Entire litters were randomized to receive either HCD or standard diet (SD), and for each
homozygous (Bcs1lG/G) mouse a littermate gender-matched wild-type (WT) or heterozygous (Bcs1lA/G)
mouse was chosen as a control animal (n = 51, of which 26 males). Heterozygous mice were included
in the control group as their phenotype is identical with that of WT mice. Homozygous mice with
matched controls were randomly selected for different assays including blood chemistry and weight
measurements (n = 6–12 in each group). The homozygous mice had low blood glucose and high
lactate-to-glucose ratio, which was unchanged by the increased dietary dextrose (Table 1). HCD had
no significant effect on blood ketone levels in control or homozygous (GG) mice as compared to
SD. The homozygous mice had reduced weight gain from weaning (at the age of 21 days, P21) to
deterioration on SD, HCD unchanged their weight (Figure 1A). Survival (Figure 1B) was significantly
shorter on HCD (28 ± 0.6 days, p < 0.0001).
Table 1. The effect of a high-carbohydrate diet (HCD) on blood chemistry in control and Bcs1lG/G
homozygous mice.
Metabolites (mmol/L) Control SD (n = 38) Control HCD (n = 26) GG SD (n = 30) GG HCD (n = 21)
Glucose 7.0 ± 0.7 6.9 ± 1.2 1.7 ± 0.6 1 2.4 ± 1.6 2
Lactate 4.0 ± 2.2 4.6 ± 1.9 3.5 ± 1.8 4.1 ± 1.2
Lactate/Glucose 0.45 ± 0.2 0.6 ± 0.2 2.0 ± 1.0 1 2.9 ± 2.4 2
Ketones 0.6 ± 0.3 0.8 ± 0.3 0.5 ± 0.2 0.7 ± 0.3
Number of samples varied in each group (n = 6 to 12). Data presented as mean ± SD. p < 0.05 when compared
with (1) Control standard diet (SD) and (2) Control high carbohydrate diet (HCD); one-way ANOVA and Tukey’s
multiple comparison.
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Figure 1. Effect of HCD-feeding (SD, standard diet; HCD, high carbohydrate diet) on weight and 
survival of Bcs1lG/G mice. (A) Weight curves of homozygous (GG) and control (CO) mice on 
respective diets from weaning to deterioration stage (n = 4–8/group). Significant differences (p < 0.05) 
are shown for comparing CO on SD with CO on HCD (*) and GG on SD (δ); and CO on HCD with 
GG on HCD (Φ), Tukey’s multiple comparison; (B) survival curve of homozygous mice (GG) on SD 
(n = 30) and HCD (n = 21). Median survival was 33 days on SD, 29 days on HCD (p < 0.0001, Log-rank, 
Mental-Cox test). 
2.2. No Effect on Hepatic Glycogen Depletion or Fat Accumulation by HCD Feeding 
Histological staining of liver sections revealed hepatopathy at end-stage disease (i.e., 
deterioration requiring sacrificing) of the homozygous mice. PAS staining showed non-fasting 
glycogen depletion in homozygotes and this was not affected by HCD. Oil Red O (ORO) staining 
showed mildly increased lipids in the hepatocytes of the homozygotes and this was not significantly 
affected by HCD (Figure 2). 
 
Figure 2. Liver histology. (A) Periodic acid–Schiff (PAS) staining showing reduced glycogen in the 
livers of Bcs1lG/G mutant mice (GG) on both high-carbohydrate (HCD) and standard (SD) diets. Oil 
Red O (ORO) staining showing slightly increased lipid accumulation in the GG mice on SD and on 
HCD but the difference was not statistically significant; (B,C) Image quantification of PAS (n = 9–11) 
and ORO (n = 4) staining in the liver sections. p-Values: **** p < 0.0001. 
  
Figure 1. Effect of HCD-feeding (SD, standard diet; HCD, high carbohydrate diet) on weight and
survival of Bcs1lG/G mice. (A) Weight curves of homozygous (GG) and control (CO) mice on respective
diets from weaning to deterioration stage (n = 4–8/group). Significant differences (p < 0.05) are shown
for comparing CO on SD with CO on HCD (*) and GG on SD (δ); and CO on HCD with GG on HCD
(Φ), Tukey’s multiple comparison; (B) survival curve of homozygous mice (GG) on SD (n = 30) and
HCD (n = 21). Median survival was 33 days on SD, 29 days o HCD (p < 0.0001, Log-rank, Mental-Cox test).
2.2. No Effect on Hepatic Glycogen Depletion or Fat Accumulation by HCD Feeding
Histological staining of liver sections revealed hepatopathy at end-stage disease (i.e., deterioration
requiring sacrificing) of the homozygous mice. PAS staining showed non-fasting glycogen depletion in
homozygotes and this was not affected by HCD. Oil Red O (ORO) staining showed mildly increased
lipids in the hepatocytes of the homozygotes and this was not significantly affected by HCD (Figure 2).
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2.3. No Effect on Respiratory Chain (RC) Complex Assembly or Respiration in Liver Mitochondria by
HCD Feeding
The homozygous Bcs1lc.232A>G mutation results in decreased amount of BCS1L and RISP proteins
in liver mitochondria [15]. Using Blue Native PAGE (BNGE) and immunoblotting we found no effect
of HCD on this depletion. The RISP subunit was localized in supercomplex (SC1) indicating that fully
assembled CIII participates in supercomplex formation. The antibody against subunit Core1 detected,
in addition, a precomplex of III (pre-CIII) with a smaller molecular size than the fully assembled CIII
in control (CO) animals. The homozygous mice had increased amount of complex I (CI) and complex
IV (CIV) on SD (Figure 3A). They had low mitochondrial respiration at both coupled (54% of CO) and
uncoupled (63% of CO on SD) state and this was not affected by the HCD (Figure 3B).
Int. J. Mol. Sci. 2016, 17, 1824 4 of 13 
 
2.3. No Effect on Respiratory Chain (RC) Complex Assembly or Respiration in Liver Mitochondria by  
HCD Feeding 
The homozygous Bcs1lc.232A>G mutation results in decreased amount of BCS1L and RISP proteins 
in liver mitochondria [15]. Using Blue Native PAGE (BNGE) and immunoblotting we found no 
effect of HCD on this depletion. The RISP subunit was localized in supercomplex (SC1) indicating 
that fully assembled CIII participates in supercomplex formation. The antibody against subunit 
Core1 detected, in addition, a precomplex of III (pre-CIII) with a smaller molecular size than the 
fully assembled CIII in control (CO) animals. The homozygous mice had increased amount of 
complex I (CI) and complex IV (CIV) on SD (Figure 3A). They had low mitochondrial respiration at 
both coupled (54% of CO) and uncoupled (63% of CO on SD) state and this was not affected by the 
HCD (Figure 3B). 
 
Figure 3. Respiratory chain (RC) complex assembly and respiration in liver mitochondria. (A) BNGE 
analyses show respiratory chain complexes in liver mitochondria as follows: NDUFV1 (CI), NADH 
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pyruvate dehydrogenase E1; and ETFAα, electron transport flavoprotein alpha-polypeptide. HCD had 
no effect on RC complex assembly; (B) Liver mitochondrial respiration at coupled and uncoupled 
state; uncoupling between rate of respiration and ATP production was induced by carbonilcyanide 
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Figure 3. Respiratory chain (RC) co l l d respiration in liver mitochondria. (A) BNGE
an lyse how respiratory chain co l it chondria as follows: NDUFV1 (CI), NADH
dehydrogenase ( i i one) complex I; II, Complex II; CIII, Complex III; CIV, Complex IV;
PDHE1α, pyruvate dehydrogenase E1; and ETFAα, electron transport flavoprotein alpha-polypeptide.
HCD had no effect on RC complex assembly; (B) Liver mitochondrial respiration at coupled and
uncoupled state; uncoupling between rate of respiration and ATP production was induced by
carbonilcyanide p-tri-flouro-methoxy-phenyl-hydrazone (FCCP) (n = 3–4). HCD had no effect on
respiration. SC1, supercomplex. p-Values: * p < 0.05.
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2.4. Altered Plasma Metabolome in Bcs1l Mutant Mice and Partial Normalization of Amino Acid Metabolism
and Urea Cycle by HCD Feeding
Using false discovery rate (FDR) < 10% (p < 0.05) in targeted plasma metabolomics analysis,
significant alterations were observed in 62/101 metabolites (Table S1) due to the mutation and
HCD. The effects on metabolites in the different mouse groups are presented in a Venn diagram
(Figure 4B). The mutation alone changed 48 plasma metabolites including amino acid derivatives (23),
bile acids (4), neurotransmitter intermediates (3), nucleosides and bases (5), acyl-carnitines (4), urea
cycle (2) and other metabolites (7). Most of these were significantly increased in homozygotes on
SD, as compared with controls, but some metabolites such as arginine, L-glutamic acid, free and
short acyl-carnitines (except isobutyryl-carnitine), normetanephrine, some nucleosides and bases,
trimethylamine-N-oxide, cotinine and succinate (Figure 4D, Table S1) were decreased. On both diets,
homozygous mice had significantly increased sucrose (p < 0.001) in plasma (Table 2). Feeding HCD to
the homozygotes changed 28 metabolites including 11 amino acids, 3 neurotransmitter intermediates
and 14 other metabolites. Kynurenic acid, creatinine, 5-hydroxy-3-indoleacetic acid, 4-pyridoxic
acid, and symmetric-dimethyl arginine were higher in homozygotes on HCD than on SD (Table 2).
The combined concentration of aromatic amino acids (AAA) was normalized to CO level by HCD
in homozygotes (Figure 4C). Quantitative enrichment analysis shows the metabolic pathways that
were significantly altered by the mutation (Figure 5A, Table S2) and diet (Figure 5B, Table S3) in
Bcs1lG/G mice.
Table 2. The effect of HCD on plasma metabolomics in control and homozygous (GG) mice.
Metabolites (mmol/L) Control SD (n = 12) Control HCD (n = 6) GG SD (n = 6) GG HCD (n = 6)
Amino acid derivatives
Asymmetricdimethylarginine 4.05 ± 0.7 3.39 ± 0.64 5.55 ± 1.51 1 4.39 ± 0.7
Asparagine 136 ± 29.8 144 ± 75.1 432 ± 164.6 1 311 ± 113 2
Creatinine 5.23 ± 1.2 5.19 ± 0.95 5.6 ± 1.93 13.2 ± 5.4 2,3
Dimethylglycine 8.03 ± 3.7 3.92 ± 1.9 30.1 ± 11.3 1 13.3 ± 4.8 3
Glutamine 918 ± 185 831 ± 65.2 2547 ± 754 1 1457 ± 363 2,3
Glycine 354 ± 116 246 ± 62.8 897 ± 229 1 619 ± 242 2,3
Kynurenic Acid 0.06 ± 0.03 0.102 ± 0.04 0.12 ± 0.08 0.57 ± 0.36 2,3
Leucine 149 ± 50.9 211 ± 117 413 ± 119 1 269 ± 69.9 3
Phenylalanine 43.9 ± 8.8 56.6 ± 13.5 98.0 ± 21.4 1 64.8 ± 16.2 3
Symmetricdimethylarginine 1.3 ± 0.26 1.1 ± 0.42 1.72 ± 0.43 2.3 ± 0.4 2,3
Tyrosine 55.2 ± 11.8 86.5 ± 23.6 164 ± 67.9 1 93.7 ± 37.9 3
Neurotransmitter
intermediates
5-Hydroxyindole-3-acetic acid 0.23 ± 0.13 0.32 ± 0.14 0.69 ± 0.47 3.18 ± 1.9 2,3
L-5-Hydroxytryptophan 0.024 ± 0.008 0.04 ± 0.02 0.09 ± 0.04 1 0.06 ± 0.02 3
Normetanephrine 0.018 ± 0.006 0.02 ± 0.006 0.005 ± 0.002 1 0.02 ± 0.012 3
Others
4-pyridoxic acid 0.045 ± 0.03 0.036 ± 0.03 0.11 ± 0.1 0.32 ± 0.23 2,3
Adenine 0.006 ± 0.003 0.005 ± 0.001 0.005 ± 0.001 0.009 ± 0.005
Adenosine 0.05 ± 0.03 0.05 ± 0.02 1 0.08 ± 0.025 0.10 ± 0.05 1,2
cAMP 0.007 ± 0.003 0.007 ± 0.002 0.01 ± 0.003 0.015 ± 0.007 1,2
Chanodeoxycholic acid 41.7 ± 20.4 472 ± 717 1295 ± 1578 1 257 ± 356
Cholic Acid 9.8 ± 11.5 25.1 ± 38.7 428 ± 228.6 1 23.4 ± 14.24 3
Cotinine 0.011 ± 0.003 0.01 ± 0.005 0.005 ± 0.002 1 0.01 ± 0.005 3
Glyceraldehyde 48.9 ± 14.6 67 ± 21.5 115 ± 27.01 1 71.9 ± 12 3
Glycocholic acid 0.46 ± 0.14 0.21 ± 0.07 0.67 ± 0.49 2 0.36 ± 0.16
Isobutyryl carnitine 0.037 ± 0.01 0.022 ± 0.01 0.06 ± 0.02 1 0.024 ± 0.01 3
Nicotinic acid 0.11 ± 0.06 0.08 ± 0.04 0.29 ± 0.29 0.12 ± 0.57
Ornithine 71.8 ± 11.3 86.5 ± 20.7 297 ± 75.4 1 190 ± 43.8 3
Pantothenic acid 3.9 ± 1.14 5.4 ± 1.6 2.56 ± 0.73 5.64 ± 2.4 3
Sucrose 0.2 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 1 0.4 ± 0.1 2
Data are presented as mean ± SD. p < 0.05 when compared with Control SD (1), Control HCD (2) and GG SD (3).
One-way ANOVA and Tukey’s multiple comparisons.
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3. Discussion
The phenotype of the homozygous Bcs1lc.232A>G mutant mice mimics the clinical characteristics
of the GRACILE syndrome, including growth failure, progressive liver disorder wit microvesicular
steatosis, proxi al tubulopathy, and reduc d survival [14,16]. Their liver mitochondria show
changes in composition RC com lexes: a decreased amou t of th BCS1L protein is accompanied
by decr ased amount of Rieske protein in mitochondria and increased amount of CI and CIV.
Furth more, a precomplex of CIII participates in supercomplex formation but CIV amount is low in
supercomplexes [15]. These findings were verified in the present study.
We performed targeted plasma metabolite profiling and show changes in several key metabolites
in the homozygous mice. Due to their hypoglycemic state, the homozygotes initially depend on
glycogenolysis for energy production, which depletes liver glycogen. As previously shown by liver
tissue metabolomics investigation [17], we found a reduction in plasma short-acyl carnitines (except
isobutyryl-carnitine), indicating a defect in fatty acid metabolism. Deficits in carbohydrate and fatty
acid metabolism are likely the cause of the starvation-like condition and subsequent increased protein
catabolism [18]. The associated increases in glucogenic (alanine, asparagine, glycine, dimethylglycine,
histidine, methionine, proline, serine and valine) and ketogenic (leucine, isoleucine, phenylalanine
and tyrosine) amino acids in circulation support the conclusion of a starvation-like condition in our
previous liver metabolomics investigation [17]. The increased plasma aromatic amino acids indicate
abnormal liver function and increased protein catabolism, as in patients with liver cirrhosis [19,20].
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Moreover, increased alanine, glycine, proline and tyrosine have been considered to be markers of
mitochondrial dysfunction in other disease models [21].
In skeletal muscle, glucogenic amino acids can be utilized to synthesize glucose and produce
pyruvate. Transamination by excessive nitrogen produced from protein degradation converts pyruvate
to alanine. The alanine is transported by the blood stream to the liver, where deamination converts
it back to pyruvate. This glucose-alanine transport from muscle to liver tissue is known as Cahill
cycle [22]. In the Bcs1lG/G mice, plasma branched-chain amino acids (BCAA) were increased, which is
contrary to the low BCAA levels found in pyruvate dehydrogenase (PDH) deficiency model [21,23].
This suggests that pyruvate to acetyl-CoA conversion may be undisrupted in the Bcs1lG/G mice. In the
liver, ketogenic amino acids can be utilized to produce ketone bodies and transported to other organs.
Krebs cycle intermediates such as acetyl-CoA, alpha-ketoglutarate, succinyl-CoA, fumarates and
oxaloacetate can be synthesized from amino acids by transamination and oxidative deamination [24].
Deamination of amino acids releases ammonia which will be processed in the urea cycle. Thus,
increased alanine and urea cycle intermediates (citrulline and ornithine) in the homozygous mice
suggest activated Cahill cycle and possible hyperammonemia. We found decreased succinate in the
plasma, but our previous study showed elevated succinate and fumarate in liver tissue [17], suggesting
that circulating succinate is not indicative of its accumulation in the liver.
Unlike liver and muscle, brain tissue can utilize both glucose and ketones as energy source.
In order to maintain constant energy supply to the brain, glycogenolysis and gluconeogenesis
are carried out in renal proximal tubules as well as in the liver. However, a combined defect in
both liver and renal tissue affects glucose homeostasis [8] and thereby energy supply to the brain.
During hypoglycemia, brain tissue absorbs tryptophan and produces of 5-hydroxyindoleacetic acid
(5-HIAA) and glutamine [16]. We found metabolite changes in the homozygous mice indicating such
a derangement, i.e., increased plasma glutamine and 5-hydroxytryptophan (5HTP), an intermediate
of 5-HIAA synthesis. Furthermore, we found increased kynurenine (KYN) and nicotinamide
adenine dinucleotide (NAD) in homozygous mice. Increased KYN and its derivatives play a role in
depression [25], age-associated chronic inflammation [26] and reduced insulin activity [27]. Especially
in patients with diabetic retinopathy and other mitochondrial dysfunction, increased levels of KYN
and 3-hydroxy kynurenine were found in serum samples [28]. Taken together, our findings suggest
that the hypoglycemic condition in the Bcs1lG/G mutant mice induces a stress resulting in an enhanced
tryptophan pathway and increased neurotransmitters such as GABA and 5-HTP. In addition, some of
the elevated metabolites have previously been connected to chronic kidney disease, such as significant
increases in phenylalanine, N2-succinyl-L-ornithine, L-proline, creatinine and KYN in chronic renal
failure [29] and Kidney-Yang deficiency syndrome [30]; increased symmetric dimethylarginine in
diabetic nephropathy [31], and asymmetric dimethylarginine accumulation in cardiovascular disease
caused by renal failure [32]. Increased kynurenic acid (KYNA) is found in late stage of chronic kidney
disease [33]. Increased creatinine is the most common clinical biomarker of renal dysfunction [29,34],
also found in Toni–Debré–Fanconi syndrome, which is a typical tubulopathy linked to several different
mutations in BCS1L in newborn infants [35] and other mitochondrial diseases [36,37]. The increase
of these biomarkers in homozygous mice on HCD suggests a more severe renal dysfunction than
in mice fed with SD. Interestingly, we found increased sucrose concentrations in the plasma of the
homozygous mice. As sucrose is neither synthesized in the body nor absorbed in the intestine, it has
been suggested as a marker of gastric mucosal damage leading to non-specific absorption in several
animal species [38]. This finding may warrant further investigation of gut mucosal integrity in the
Bcs1l mutant mice.
In this dietary intervention, the substitution of glucose (dextrose) for corn starch and increasing
the total amount of carbohydrate from 44.2% to 65.8% did not improve glycemic balance, growth, or
end-stage disease in the mutant mice, but instead caused an unexpected decrease in survival. We chose
a HCD with dextrose/glucose instead of sucrose to avoid fructose that may be harmful to the liver
at high intake level in mice [39]. High glucose diet is known to induce fatty acid accumulation in
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liver of wild-type C57BL/6J mice [40] and in carnitine palmityoltransferase 1a deficiency models [10].
Both control and homozygous mice on HCD had marginally increased lipid accumulation in liver as
assessed by ORO staining. The liver disease in Bcs1l mutant mice is not severe enough to be the cause
of death. Thus, a hepatic adverse effect caused by the HCD is unlikely to explain the reduced survival.
Protein content was similar in the diets but the HCD contained 24% less (w/w) fat than the control diet
(18.0% vs. 12.9% of energy from fat), which could have adversely affected the energy metabolism in
the homozygous mice if there was increased need for β-oxidation due to the RC deficiency.
HCD did not affect liver glycogen depletion, mitochondrial respiration or CIII assembly, indicating
no overall effect on liver disease progression. Given the reduced survival on HCD it was surprising that
plasma phenylalanine and tyrosine concentrations were normalized by HCD, suggesting correction of
increased protein catabolism. However, HCD feeding resulted in normalization of some amino acids,
such as glycine, phenylalanine and tyrosine, which might reduce ammonia release and normalize the
urea cycle intermediate ornithine. Our previously liver metabolomics investigation showed signs of
oxidative stress at end-stage disease [17]. High-glucose diet has been reported to increase oxidative
stress in the liver of wild-type C57BL/6J mice [40]. Here, HCD induced the tryptophan pathway,
which can lead to increased synthesis of 5-HIAA and KYNA. KYNA is a metabolite with antioxidant
and reactive oxygen species scavenging properties [41]. In addition, significantly increased 4-pyridoxic
acid in plasma suggests vitamin B6 catabolism [42], which is normally induced during inflammation
to reduce oxidative and aldehyde stress [43]. These changes suggest a response to increased oxidative
stress in the Bcs1lG/G mice on HCD.
In conclusion, our results suggest that oral dextrose supplementation or high carbohydrate diet
formulations may not be efficient in improving the glycemic balance in CIII deficiency and may, in fact,
cause adverse effects. Both the Bcs1l mutation and the dietary modification had a marked effect on
plasma metabolome in the mice, which suggests that targeted plasma metabolomics can be a valuable
tool when assessing disease progression and potential therapies in mitochondrial disorders and their
animal models.
4. Materials and Methods
4.1. Animal Experiments
Homozygous mice in congenic C57BL/6 (substrain C57BL/6NCrlLtcf) background were used [15].
Breeding pairs were randomized to HCD using Harlan 60% Dextrose diet (TD05256) or standard Harlan
diet (Teklad Globel 18% Rodent Diet—2018) to familiarize the pups from birth with the allocated
diet (Table S4). Dextrose is a D-glucose and can be directly absorbed in the intestine. Water was
available ad libitum in a vivarium with 12 h light/dark cycle at 22 ◦C. DNA was isolated from tail
biopsies and used for Bcs1l genotyping [8]. WT or heterozygous (Bcs1lA/G) animals, which do not
have any mitochondrial dysfunction, born in the same litter as the homozygotes (Bcs1lG/G) were used
as controls. A standardized health score was developed based on waddling gait, reduced curiosity,
lack of movement in the cage, appearance of kyphosis, deterioration of balance and loss of grip
strength. Each behavioral item was scored from zero to two (0 for normal, 1 for slight abnormality
and 2 for clear abnormality). When weight gain was decreased compared to the littermate control WT
(or heterozygous) mouse, scoring was performed in connection with the daily weighing procedure.
When the score was ≥7/12 or no weight gain occurred, the animals were considered as having
end-stage disease and were sacrificed before spontaneous death. Mice were anesthetized briefly with
isoflurane (792632 Sigma-Aldrich, St. Louis, MO, USA) and blood drops were obtained from the tail
artery by pinching with needle for measurement of glucose, lactate and ketone concentrations with
Freestyle Lite (Abbot Laboratories, Abbott Park, IL, USA), Lactate Pro (Arkray, Kyoto, Japan) and
FreeStyle Precision (Abbot) meters, respectively. The mice were sacrificed by cervical dislocation and
thoracic cavity was opened to collect blood with a cardiac puncture. The blood was immediately
transferred into Li-heparin vials (Vacuette 454089, Greiner Bio-One International Gmbh, Kremsmunster,
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Austria). The vials were kept on ice and centrifuged at 2000× g for 10 min to isolate plasma, which
was stored at −80 ◦C.
4.2. Ethics Statement
Animal experiments were performed according to national guidelines with the approval of the
Lund regional animal research ethics committee (permission M245-11, 19 October 2011). All efforts
were taken to ameliorate suffering.
4.3. Tissue Sampling
Tissue samples were collected for histology, mitochondrial isolation and snap-freezing,
respectively, immediately after sacrificing. The complete data samples were not obtained from each
animal due to ethical and practical reasons (See Table S5). Respirometry analyses were performed
immediately [15], liver mitochondria isolated, and samples stored at −80 ◦C for subsequent assays.
4.4. Histology
Liver sections were stained with standard methods to assess general histology (hematoxylin-eosin,
H & E), glycogen content (PAS, PAS-Diastase), and fat content (Oil Red O, ORO). The area of staining
from the image was quantified using Fiji imageJ software (National Institutes of Health, Bethesda,
MD, USA) [44].
4.5. Respiratory Chain Assessment in Liver Mitochondria by Respirometry and BNGE
From liver specimens mitochondria were isolated by sequential centrifugation including
density purification on 19% Percoll (GE Healthcare, Amersham, UK) as previously described [15].
Respiratory chain function was assessed by measuring oxygen consumption in freshly isolated
mitochondria using a substrate uncoupler inhibitor titration (SUIT) protocol in Oroboros Oxygraph-2k
with DatLab 4 software (Oroboros Instruments, Innsbruck, Austria) as previously described [15].
Structural assessment of mitochondrial complexes and supercomplexes were performed from isolated
mitochondria with BNGE as described earlier [15]. Proteins separated by BNGE were blotted onto
polyvinylidine difluoride membranes using iBlot™ equipment (Invitrogen, Carlsbad, CA, USA).
Membranes were blocked in PBS supplemented with 0.05% Tween 20 and 5% dry milk for subsequent
antibody incubation. Most antibodies directed against respiratory chain complex subunits were
obtained from MitoSciences (Eugene, OR, USA); for CIII subunits Core1 (MS303) and RISP (MS305)
were used, and for CIV subunit I (COX1, MS404). An antibody directed against ETFAα (MS782) was
used as loading control. An antibody detecting the CI subunit NDUFV1, which is incorporated in
the complex at the final assembly stage, was obtained from Sigma Aldrich (Stockholm, Sweden).
Primary antibodies were detected by incubation with HRP-coupled goat anti-mouse secondary
antibody (DAKO Cytomation, P0447). Membranes were developed with ECL plus (GE Healthcare,
Amersham, UK).
4.6. Metabolomics Analysis from Plasma
The isolated blood plasma samples were used to measure 101 targeted metabolites by a triple
quadrupole mass spectrometer coupled to ACQUITY UPLC system (Waters Corporation, Milford, MA,
USA) in the metabolomics core facility at the Institute for Molecular Medicine Finland (FIMM) [45].
Quantified data were further processed by online tool, MetaboAnalyst 3.0 (McGill University, QC,
Canada, http://www.metaboanalyst.ca). Data were auto scaled (mean-centered and divided by the
standard deviation of each variable) to perform correlation and enrichment analysis. Unsupervised
PCA was used to identify variation in data set. Dendogram was plotted based on Ward and each cell
represents concentration values. Bar-graphs were plotted for selected individual metabolites with
mean and standard deviation.
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4.7. Statistics
Statistical differences in blood chemistry, histology, metabolomics were analyzed by one-way
ANOVA (Tukeys multiple comparison). Differences in survival curves were analyzed by log-rank,
Mental-Cox test. Respirometry data were analyzed by two-way ANOVA (Tukeys multiple comparison).
We used GraphPad Prism 5.02 software (GraphPad Software Inc., La Jolla, CA, USA) for analysis and a
p-value <0.05 was considered significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1824/s1.
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